THERADIAG SA of Croissy Beaubourg at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Manufacturers

THERADIAG SA

14 rue Ambroise Croizat, 77183 Croissy Beaubourg
France

Telephone +33 1 64621012
info@theradiag.com

This company is co-exhibitor of
Business France

Hall map

MEDICA 2017 hall map (Hall 3): stand H74

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  • 03.02.16.01  Diagnostic agents / kits for determination of therapeutic drugs

Diagnostic agents / kits for determination of therapeutic drugs

Our products

Product category: Therapeutic drug monitoring, Diagnostic agents / kits for determination of therapeutic drugs

Monitoring the treatment of patients treated by anti-TNFα

Anti-TNFαs are therapeutic treatments widely prescribed to treat more than 50,000 patients affected by various chronic inflammatory pathologies. They consist of biomarkers capable of binding TNFα and blocking the action of the TNFα that is responsible for the inflammatory state.

Infliximab, Adalimumab, and Etanercept are anti-TNFα biologics recommended for treating pathologies such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylarthritis, and psoriasis . These biotherapies represent a cost of some €1 billion in France.

Whatever the anti-TNF-α, some authors have demonstrated the appearance of anti-drug neutralizing antibodies (ADAb = Anti-Drug Antibodies) among patients presenting therapeutic resistance (20% to 60% of treated patients). This presence of ADAb appears as a precursor to potential clinical deterioration (therapeutic escape).

The LISA TRACKER Premium kits are the first CE marked kits allowing simultaneous dosage of three parameters within three hours of reaction from a serum sample:

  • Circulating TNFα is one of the main markers involved in the inflammatory process. TNFα is a complex predictive marker that may lead to new areas of research.
  • Prescribed anti-TNF-α (Infliximab, Adalimumab, Etanercept, Certolizumab-pegol, golimumab) to optimize dosage consistent with the presence or absence of ADAb.
  • The presence of antibodies directed against the medication (ADAb), of which authors have reported the presence among patients experiencing loss of drug efficacy.
These kits allow clinicians to monitor the patient’s trough plasma levels of these three parameters over time. The combination of these three parameters allows them to anticipate, optimize, and better manage the patient’s treatment.

More Less

Product category: Therapeutic drug monitoring, Diagnostic agents / kits for determination of therapeutic drugs

Our platform

MicroRNAs: promising biomarkers

Only 1 to 2% of the human genome is translated into proteins. Non-coding DNA has long been considered as junk DNA with no biological function. It is now acknowledged that almost 90% of the sequence is transcribed into noncoding RNA, including microRNAs.
MicroRNAs are small, noncoding RNAs that control gene expression. Their mode of action involves pairing with target RNAs with which they are partially compatible. This hybridisation represses translation of the corresponding protein or cleaves the RNA. Numerous studies have shown that modulation of RNA expression results in many pathological situations. Since their discovery, over 2000 microRNAs have been characterised. Some microRNAs are released into blood and can serve as biological markers. In this way, microRNA expression modulations in pathologies such as cancers and chronic inflammatory diseases place them as key diagnostic and prognostic biomarkers. These discoveries have opened up new perspective by offering tremendous potential clinical application.

More Less

About us

Company details

Founded in 1986 by two former employees of Abbott France, Theradiag has been dedicated, at first, to distributing in vitro diagnostics, specifically for autoimmune diseases. The main stages of Theradiag’s development are the following:

2012
IPO of the company on NYSE Alternext on December 11th, 2012.

BMD becomes Theradiag.

2011
Patent filing for the monitoring of the treatment of autoimmune diseases by anti-TNFα, through multiple bio markers.

2010
Appointment of Michel Finance as Theradiag’s Chief Executive Officer.

2010
Launch by Theradiag in France, as part of an exclusive partnership, of two genetic and oncogenetic products supplied by the U.S. company Asuragen, expert in molecular biology and microARN technology.

2010
CE marking of the first Lisa-Tracker kit to monitor the treatment of autoimmune diseases by anti-TNFα.

2008
First financial support by OSEO Innovation, through a reimbursable fund of €550,000, for the development of a multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNFα.
Initial growth of the Company in theranostics under the strategic industrial innovation plan, TRACKER, carried out in partnership with the French biotech company Neovacs. As part of OSEO Innovation’s support, Theradiag has already received some €1.5 million (in subsidies and reimbursable advances), notably to develop a universal solution to monitor the treatment of autoimmune diseases.

2006
Awarded  “Innovative Company” for three years for its Innovation Mutual Funds (FCPI), by OSEO Innovation

2004
Commercial launch of FIDIS™, a line of autoimmune kits based on Luminex’s Multiplex technology and automated instruments.

2000
First fund-raising from venture capitalists to finance the Company’s growth.

2000
Expansion of its international distribution network by creating an export department and signing its first distribution partnerships.

1999
Signing of a development and sub-contracting agreement with the U.S. company Luminex to allow Theradiag to use Multiplex technology to develop an in house range of diagnostic materials and kits for autoimmune diseases diagnosis.

1992
Commercialization of the Company’s first in house products.

1990
Theradiag’s development into activities to complement research and development and production.

More Less